BIO-TECH Systems, Inc. - Report #230: The World Market for Therapeutic Radiopharmaceuticals

Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes

Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189


	HOME

	ABOUT BIO-TECH SYSTEMS

	AUTHOR'S C.V.

	BREAKING MARKET NEWS

	REPORT #280 The Market for PET Radiopharmaceuticals & PET Imaging New! Released in Jun. 2008!

	REPORT #270 The U.S. Market for Diagnostic Radiopharmaceuticals New! Released in Nov. 2007!

	REPORT #260 The U.S. Market for Medical Imaging Contrast Media

	REPORT #230 The World Market for Therapeutic Radiopharmaceuticals
Report Contents
Partial List of Exhibits

	REPORT #170 The U.S. Market for Brachytherapy Products

	ORDERS

	NEWS RELEASES

	CONTACT US

THE WORLD MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS

BIO-TECH SYSTEMS INC. announces the publication of:

BIO-TECH Report #230, The World Market for Therapeutic Radiopharmaceuticals

The Therapeutic Radiopharmaceutical Report Includes:

Market Prospects for Therapeutic Radiopharmaceuticals
Emerging Markets for New Targeted Antibodies and Peptides
Developments in Therapeutic Isotopes with Enhanced Performance
Analysis of Industry Alliances and Partnerships
Technological Trends and Competitive Challenges
Market Assessment and Sales Forecasts to 2012

Therapeutic radiopharmaceuticals include both current and emerging products for lymphoma, colon cancer, lung cancer, prostate cancer, breast cancer, endocrine cancer, myeloma, brain cancer, liver cancer, pancreatic cancer and other cancers resistant to traditional therapies. There has been a surge in research activity to expand applications for therapeutic radiopharmaceuticals employing more sophisticated targeting methodologies and more appropriate therapeutic isotopes for the tumors being treated. There is also more confidence with respect to the prospects for FDA approval of these drugs. As interest in new therapeutic radiopharmaceuticals has grown, it has prompted investigators to utilize different isotopes with more appropriate energy levels and half-lives for specific applications. The objective has been to minimize toxicity and reduce the bystander effect on neighboring healthy cells. There is also considerable research involving alpha emitters, where the shorter particle range and high-energy deposition can be used to advantage to destroy DNA directly. There are a number of products in development employing bismuth 212, bismuth-213, astatine-211, radium-223 and polonium-210.

The report has a strong focus on new products and technology and emerging market opportunities. The prospects for therapeutic radiopharmaceuticals are on a major threshold with the approval of Zevalin and Bexxar for treating non-Hodgkins lymphoma. This will be followed by other radioimmunotherapy products for both circulating and solid tumors, which should form a sound base for continued investment in this field. As these products enter the mainstream, there will be others in the pipeline for treating a variety of cancers. One motivator is the potential return on investment. The high pricing of these products is justified by their unique status and is indicative of future market opportunities, even in the presence of competition.

Market Analysis and Future Prospects
U.S. sales of therapeutic radiopharmaceuticals were still on the threshold in 2005, with total sales of $71 million. Rapid growth is anticipated over the next 5-6 years. By 2012, therapeutic product sales should reach $1.9 billion, with high continuing growth beyond that time. This will be based on the introduction of new therapeutic radiopharmaceuticals for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers. These agents will be used in conjunction with traditional therapies, enhancing their effectiveness, with better specificity and reduced side effects. As interest in new therapeutic radiopharmaceuticals increases, it will prompt investigators to utilize different isotopes with more focused capabilities for treating various tumors, reducing the bystander effect on neighboring healthy cells. Use of these new agents will reduce treatment time and accelerate recovery for many patients. It will also offer an attractive investment opportunity for many of the companies and venture groups supporting these programs.

Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #230. If you are interested in purchasing BIO-TECH Report #230, please follow this link to our Online Order Form.

To download a detailed Table of Contents (TOC) for BIO-TECH Report #230, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.

Download TOC in MS Word format (122KB)

Download TOC in Adobe PDF format (45KB)

Report Contents | Partial List of Exhibits

Report #230 Home Page

Download Report #230 Table of Contents:

BTSI230.doc -OR-

BTSI230.pdf

Send this page to a friend